Results 11 to 20 of about 14,372 (211)
Raltegravir in treatment naïve patients
European Journal of Medical Research, 2009 Raltegravir is the first integrase inhibitor approved for the treatment of HIV infection based on the superior efficacy it showed compared to optimized backbone therapy alone in patients harboring multidrug resistant viruses.
Cossarini F, Castagna A, Lazzarin A
doaj +3 more sources
Drug-drug interactions with raltegravir
European Journal of Medical Research, 2009 Objective To review all currently published drug-drug interaction studies with the HIV-integrase inhibitor raltegravir. Methods A PubMed search was conducted for all published reports up to August 1, 2009 as well as a review of updated European and US ...
Burger David M
doaj +2 more sources
Adverse events of raltegravir and dolutegravir [PDF]
AIDS (London), 2017 Objective: To compare the frequency and risk factors of toxicity-related treatment discontinuations between raltegravir and dolutegravir. Design: Prospective cohort study.
L. Elzi +8 more
semanticscholar +4 more sources
Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy
Infection and Drug Resistance, 2010 Charlotte Charpentier1, Laurence Weiss21Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Laboratoire de Virologie, Université Paris-Diderot, Paris, France; 2Assistance Publique-Hôpitaux de ...
Charlotte Charpentier, Laurence Weiss
doaj +2 more sources
Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection
Infection and Drug Resistance, 2010 Lisa M Chirch, Roy T SteigbigelDivision of Infectious Diseases, Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York, USAAbstract: Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is the first available agent in a ...
Lisa M Chirch, Roy T Steigbigel
doaj +1 more source
Dissolution Enhancement of Raltegravir by Hot Melt Extrusion Technique
Iraqi Journal of Pharmaceutical Sciences, 2018 The objective of the study to develop an amorphous solid dispersion for poorly soluble raltegravir by hot melt extrusion (HME) technique. A novel solubility improving agent plasdone s630 was utilized.
Ahmed S. Abdul Jabbar
doaj +3 more sources
Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial [PDF]
PLoS Medicine, 2018 Background In sub-Saharan Africa, individuals infected with HIV who are severely immunocompromised have high mortality (about 10%) shortly after starting antiretroviral therapy (ART).
C. Kityo +24 more
semanticscholar +2 more sources
Long-term efficacy and safety of raltegravir in the management of HIV infection
Infection and Drug Resistance, 2014 Michelle D Liedtke, C Ryan Tomlin, Staci M Lockhart, Misty M Miller, R Chris Rathbun Department of Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA Abstract: Raltegravir is ...
Liedtke MD +4 more
doaj +1 more source
Antiviral Therapy, 2022 We report a case of an infant with HIV receiving raltegravir granules for oral suspension and rifampicin-based TB prophylaxis. Raltegravir trough levels remained subtherapeutic and viral load increased during concurrent rifampicin therapy despite using ...
Marlotte AA van der Veer +6 more
doaj +1 more source
Journal of Antimicrobial Chemotherapy, 2021 OBJECTIVES The second-generation integrase strand transfer inhibitor (INSTI) bictegravir is becoming accessible in low- and middle-income countries (LMICs), and another INSTI, cabotegravir, has recently been approved as a long-acting injectable.
E. Ndashimye +10 more
semanticscholar +1 more source